CXCL10 and cancer: This creates a positive feedback loop that perpetuates chronic inflammation and drives immunosuppressive responses seen in cancers such as hepatocellular carcinoma and gastric cancer.44 In addition, increased CXCL10 expression and activation of its downstream signaling components are increasingly associated with resistance to therapies, including immune checkpoint inhibitors and conventional chemotherapeutics.45